BTN3A2 hFc Chimera, Human
BTN3A2 HFc Chimera, Human

The purity of BTN3A2 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

BTN3A2 HFc Chimera, Human

BTN3A2 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

BTN3A2 hFc Chimera, Human

BTN3A2/BT3.2 butyrophilin mRNA expression by tumoral cells was previously identified as a prognostic factor in a small cohort of high grade serous epithelial ovarian cancer (HG-EOC).In conclusion, BT3.2 protein is a potential prognostic biomarker for the identification of HG-EOC patients with better outcome. In contrast, high CD206 /CD68 expression is associated with high risk of disease progression.
Z05097
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
BTN3A2 (Gln30-Trp248)
Accession # P78410-1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 50.37 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 52-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • BTN3A2 HFc Chimera, Human
    • BTN3A2 HFc Chimera, Human

    The purity of BTN3A2 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • BTN3A2 HFc Chimera, Human
    • BTN3A2 HFc Chimera, Human

    BTN3A2 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background BTN3A2/BT3.2 butyrophilin mRNA expression by tumoral cells was previously identified as a prognostic factor in a small cohort of high grade serous epithelial ovarian cancer (HG-EOC).In conclusion, BT3.2 protein is a potential prognostic biomarker for the identification of HG-EOC patients with better outcome. In contrast, high CD206 /CD68 expression is associated with high risk of disease progression.
Synonyms BT3.2; BTF3; BTF4; BT3.3; BTN3A2; FLJ40011; BTN3.2; CD277

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.